Celldex Therapeutics Share Price (NASDAQ: CLDX)

$22.08

▲

-0.3

(-1.34%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Celldex Therapeutics Stock chart to analyse performance

Celldex Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$21.72
Today's High:$22.24
$22.08
1.63%
Downside
Day's Volatility :2.34%
Upside
0.72%
52 Weeks Low:$14.40
52 Weeks High:$47.00
$22.08
34.78%
Downside
52 Weeks Volatility :69.36%
Upside
53.02%

Celldex Therapeutics Stock Returns

Period	Celldex Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	10.52%	3.6%	0.0%
6 Months	14.06%	-7.7%	0.0%
1 Year	-46.82%	-12.6%	0.0%
3 Years	-28.02%	9.5%	-4.7%

Celldex Therapeutics, Inc. Key Stats

Check Celldex Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$22.38
Open	$22.1
Today's High	$22.24
Today's Low	$21.72
Market Capitalization	$1.5B
Today's Volume	$1.3M
52 Week High	$47.0
52 Week Low	$14.4
Revenue TTM	$5.8M
EBITDA	$-231.4M
Earnings Per Share (EPS)	$-3.01
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-27.18%

Stock Returns calculator for Celldex Therapeutics Stock including INR - Dollar returns

The Celldex Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Celldex Therapeutics investment value today

Current value as on today

₹58,708

Returns

₹41,292

(-41.29%)

Returns from Celldex Therapeutics Stock

₹46,576 (-46.58%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Celldex Therapeutics Stock

1200%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Celldex Therapeutics Stock from India on INDmoney has increased by 1200% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Celldex Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
Kynam Capital Management, LP
9.19%
BlackRock Inc
8.32%
FMR Inc
8.10%
Wellington Management Company LLP
7.88%
Vanguard Group Inc
5.96%
T. Rowe Price Associates, Inc.
5.75%

Analyst Recommendation on Celldex Therapeutics Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Celldex Therapeutics(by analysts ranked 0 to 5 stars)

Celldex Therapeutics Share Price Target

What analysts predicted

Upside of 151.88%

Target:

$55.62

Current:

$22.08

Celldex Therapeutics share price target is $55.62, a slight Upside of 151.88% compared to current price of $22.08 as per analysts' prediction.

Celldex Therapeutics Stock Insights

Price Movement
In the last 1 year, CLDX stock has moved down by -46.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 695.0K → 730.0K (in $), with an average increase of 4.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 6 quarters, -32.80M → -56.6M (in $), with an average decrease of 11.6% per quarter
CLDX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 116.5%
CLDX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 140.3%
Price to Sales
ForCLDX every $1 of sales, investors are willing to pay $253.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Celldex Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$3.6M	↓ 62.54%
Net Income	$-50.9M	↓ 66.35%
Net Profit Margin	-1.4K%	↑ 161.11%

	FY20	Y/Y Change
Revenue	$7.4M	↑ 107.61%
Net Income	$-59.8M	↑ 17.5%
Net Profit Margin	-805.88%	↑ 618.08%

	FY21	Y/Y Change
Revenue	$4.7M	↓ 37.3%
Net Income	$-70.5M	↑ 17.95%
Net Profit Margin	-1.5K%	↓ 710.16%

	FY22	Y/Y Change
Revenue	$2.4M	↓ 49.32%
Net Income	$-112.3M	↑ 59.3%
Net Profit Margin	-4.8K%	↓ 3249.55%

	FY23	Y/Y Change
Revenue	$6.9M	↑ 192.02%
Net Income	$-141.4M	↑ 25.91%
Net Profit Margin	-2.1K%	↑ 2710.83%

	FY24	Y/Y Change
Revenue	$7.0M	↑ 1.99%
Net Income	$-157.9M	↑ 11.62%
Net Profit Margin	-2.2K%	↓ 194.0%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$156.0K	↓ 96.22%
Net Income	$-32.8M	↓ 24.24%
Net Profit Margin	-21.0K%	↓ 19982.45%

	Q2 FY24	Q/Q Change
Revenue	$2.5M	↑ 1501.28%
Net Income	$-35.8M	↑ 9.25%
Net Profit Margin	-1.4K%	↑ 19595.94%

	Q3 FY24	Q/Q Change
Revenue	$3.2M	↑ 27.74%
Net Income	$-42.1M	↑ 17.52%
Net Profit Margin	-1.3K%	↑ 114.84%

	Q4 FY24	Q/Q Change
Revenue	$1.2M	↓ 63.18%
Net Income	$-47.1M	↑ 11.8%
Net Profit Margin	-4.0K%	↓ 2687.84%

	Q1 FY25	Q/Q Change
Revenue	$695.0K	↓ 40.85%
Net Income	$-53.8M	↑ 14.24%
Net Profit Margin	-7.7K%	↓ 3732.6%

	Q2 FY25	Q/Q Change
Revenue	$730.0K	↑ 5.04%
Net Income	$-56.6M	↑ 5.21%
Net Profit Margin	-7.8K%	↓ 12.99%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-39.1M	↓ 31.3%

	FY20	Y/Y Change
Profit	$-35.1M	↓ 10.19%

	FY21	Y/Y Change
Profit	$1.6M	↓ 104.51%

	FY22	Y/Y Change
Profit	$-79.9M	↓ 5147.44%

	FY23	Y/Y Change
Profit	$-111.1M	↑ 39.08%

	FY24	Y/Y Change
Profit	$7.0M	↓ 106.32%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-619.0K	↓ 118.36%

	Q2 FY24	Q/Q Change
Profit	$1.7M	↓ 374.8%

	Q3 FY24	Q/Q Change
Profit	$3.2M	↑ 87.6%

	Q4 FY24	Q/Q Change
Profit	$356.0K	↓ 88.84%

	Q1 FY25	Q/Q Change
Profit	$695.0K	↑ 95.22%

	Q2 FY25	Q/Q Change
Profit	$730.0K	↑ 5.04%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-46.4M	↓ 38.31%
Investing Cash Flow	$17.1M	↓ 42.72%
Financing Cash Flow	$16.3M	↓ 44.78%

	FY20	Y/Y Change
Operating Cash Flow	$-40.4M	↓ 12.95%
Investing Cash Flow	$-98.2M	↓ 675.05%
Financing Cash Flow	$171.2M	↑ 953.24%

	FY21	Y/Y Change
Operating Cash Flow	$-60.9M	↑ 50.75%
Investing Cash Flow	$-216.2M	↑ 120.08%
Financing Cash Flow	$272.4M	↑ 59.07%

	FY22	Y/Y Change
Operating Cash Flow	$-103.7M	↑ 70.31%
Investing Cash Flow	$89.9M	↓ 141.61%
Financing Cash Flow	$4.1M	↓ 98.5%

	FY23	Y/Y Change
Operating Cash Flow	$-107.3M	↑ 3.43%
Investing Cash Flow	$-105.8M	↓ 217.61%
Financing Cash Flow	$218.5M	↑ 5259.62%

	FY24	Y/Y Change
Operating Cash Flow	$-157.8M	↑ 47.06%
Investing Cash Flow	$-290.1M	↑ 174.27%
Financing Cash Flow	$441.4M	↑ 102.07%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-40.6M	↑ 24.91%
Investing Cash Flow	$-315.2M	↑ 84.16%
Financing Cash Flow	$436.1M	↑ 100.63%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-29.3M	↓ 27.83%
Investing Cash Flow	$-46.7M	↓ 85.18%
Financing Cash Flow	$3.7M	↓ 99.15%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-55.3M	↑ 88.69%
Investing Cash Flow	$47.8M	↓ 202.22%
Financing Cash Flow	$1.2M	↓ 66.62%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-32.5M	↓ 41.31%
Investing Cash Flow	$24.0M	↓ 49.65%
Financing Cash Flow	$386.0K	↓ 68.85%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-54.4M	↑ 67.42%
Investing Cash Flow	$43.0M	↑ 78.61%
Financing Cash Flow	$202.0K	↓ 47.67%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-44.0M	↓ 19.07%
Investing Cash Flow	$49.9M	↑ 16.07%
Financing Cash Flow	$63.0K	↓ 68.81%

Celldex Therapeutics Technicals Summary

Sell

Neutral

Buy

Celldex Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Celldex Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Celldex Therapeutics, Inc.	-0.54%	14.06%	-46.82%	-28.02%	85.77%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Celldex Therapeutics, Inc.	NA	NA	0.0	-3.41	-0.27	-0.19	NA	9.87
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Celldex Therapeutics, Inc.	Buy	$1.5B	85.77%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

Celldex Therapeutics Dividend announcements

Celldex Therapeutics Earnings
Celldex Therapeutics’s price-to-earnings ratio stands at None

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Organization	Celldex Therapeutics
Employees	186
CEO	Mr. Anthony S. Marucci M.B.A.
Industry	Health Technology

Key Management of Celldex Therapeutics, Inc.

Name	Title
Mr. Anthony S. Marucci M.B.A.	Founder, President, CEO & Director
Dr. Tibor Keler Ph.D.	Founder, Chief Scientific Officer & Executive VP
Ms. Elizabeth Crowley	Chief Product Development Officer & Senior VP
Dr. Margo Heath-Chiozzi M.D.	Senior Vice President of Regulatory Affairs
Prof. Joseph P. Schlessinger Ph.D.	Co-Founder & Member of Scientific Advisory Board
Ms. Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration
Mr. Freddy A. Jimenez Esq.	Senior VP & General Counsel
Dr. Ronald A. Pepin Ph.D.	Chief Business Officer & Senior VP
Dr. Richard M. Wright Ph.D.	Chief Commercial Officer & Senior VP
Dr. Diane C. Young M.D.	Senior VP & Chief Medical Officer

Important FAQs about investing in CLDX Stock from India :

What is Celldex Therapeutics share price today?

Celldex Therapeutics share price today is $22.08 as on August 30, 2025 at 1:29 am IST at the close of the market. Celldex Therapeutics share today touched a day high of $22.24 and a low of $21.72.

What is the 52 week high and 52 week low for Celldex Therapeutics share?

Celldex Therapeutics share touched a 52 week high of $47.00 and a 52 week low of $14.40. Celldex Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $22.08, lower by 53.02% versus the 52 week high.

How to invest in Celldex Therapeutics Stock (CLDX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Celldex Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Celldex Therapeutics Shares that will get you 0.0679 shares as per Celldex Therapeutics share price of $22.08 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Celldex Therapeutics Stock (CLDX) from India?

Indian investors can start investing in Celldex Therapeutics (CLDX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Celldex Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Celldex Therapeutics share’s latest price of $22.08 as on August 30, 2025 at 1:29 am IST, you will get 0.4529 shares of Celldex Therapeutics. Learn more about fractional shares .

What are the returns that Celldex Therapeutics has given to Indian investors in the last 5 years?

Celldex Therapeutics stock has given 85.77% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?